drugset / Trial / NCT04141150

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150

Phase 2 Unknown 130 enrolled APRINOIA Therapeutics, LLC
NaSingle-groupOpen-labelOther

Summary

The overall objective of this study is to compare the overall pattern of \[18F\]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.

Timeline

Start
2022-03-22
Primary completion
2024-09
Completion
2025-02

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]APN-1607 Diagnostic / imaging agent 259 mbq Intravenous

Indications